Trial Profile
Phase II Randomized Trial of Nivolumab With or Without Ipilimumab in Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 07 Mar 2024
Price :
$35
*
At a glance
- Drugs Ipilimumab/nivolumab (Primary) ; Nivolumab (Primary)
- Indications Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- 12 Jan 2024 Planned End Date changed from 31 Dec 2023 to 31 Dec 2024.
- 28 Jan 2023 Planned End Date changed from 31 Dec 2022 to 31 Dec 2023.
- 27 Jan 2022 Planned End Date changed from 31 Dec 2021 to 31 Dec 2022.